Date: 2012-07-23
Type of information: Fundraising
Company: Cell Medica (UK)
Investors: Imperial Innovations (UK)
Invesco Perpetual (UK)
the Cancer Prevention and Research Institute of Texas (CPRIT) (USA)
Amount: £24 million (€30.8 million)
Funding type: financing round
Planned used: These funds will enable Cell Medica to continue development of its immune reconstitution cell therapies in Europe and to launch new operations in Texas, US, focussing on cancer immunotherapy. The investment from CPRIT will fund the clinical development in the US of Cell Medica\'s novel Cytorex™ EBV therapy which treats cancers associated with the Epstein Barr Virus.
Others: Imperial Innovations, a technology commercialisation and investment group, has announced that it has invested in a £17 million funding round in portfolio company Cell Medica, a clinical stage cell therapeutics business. Invesco Perpetual and the Cancer Prevention and Research Institute of Texas (CPRIT) also participated in the round. Innovations and Invesco Perpetual committed £3 million and £4 million respectively, subject to milestones. CPRIT, a body founded in 2007 to fund cancer research and prevention programmes and services in Texas, committed the balance of £9.7 million. Following the first investment tranche, Innovations will hold a 28% stake in the business. The Wellcome Trust will also become a shareholder in the business through elected conversion of a loan security into equity.
Cell Medica\'s technology is based on the selection, activation and expansion of immune cells, specifically T-cells, which can prevent and treat a range of diseases. Its Cytovir™ product family treats life-threatening viral infections in leukaemia and lymphoma patients who have undergone bone marrow transplants. These therapies involve the reconstitution of natural cell-mediated immunity, which represents a unique benefit which cannot be matched by existing antiviral drugs. The European market launch of Cytovir™ CMV for cytomegalovirus infections is targeted for 2013 following completion of two randomised controlled studies on-going in the UK.
Cell Medica has also appointed Thomas Hecht as Chairman. A former transplant physician, Thomas was vice president of marketing at Amgen Europe until 2002, and since then has been Chairman of a number of boards including Delenex and Cytos Biotechnology AG. Maina Bhaman, Innovations Director of Healthcare Investments sits on the board of the Company.
Therapeutic area: Cancer - Oncology - Infectious diseases - Transplantation
